| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
110.01(B) |
| Last
Volume: |
507,716 |
Avg
Vol: |
759,306 |
| 52
Week Range: |
$692.45 - $1071.19 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
192,108 |
259,662 |
311,759 |
469,743 |
| Total Sell Value |
$188,697,290 |
$251,749,241 |
$294,950,701 |
$405,465,351 |
| Total People Sold |
7 |
14 |
16 |
18 |
| Total Sell Transactions |
18 |
45 |
67 |
128 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sanofi-Aventis |
|
• • • |
2019-03-08 |
4 |
S |
$412.17 |
$54,041,316 |
D/D |
(131,115) |
20,723,717 |
|
- |
|
| Yancopoulos George |
President and CSO |
• • – |
2019-02-19 |
4 |
GA |
$0.00 |
$0 |
I/I |
150,722 |
753,316 |
|
- |
|
| Yancopoulos George |
President and CSO |
• • – |
2019-02-19 |
4 |
GD |
$0.00 |
$0 |
I/I |
150,722 |
249,278 |
|
- |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2019-01-18 |
4 |
GA |
$0.00 |
$0 |
I/I |
150 |
1,547 |
|
- |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2019-01-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
150 |
7,096 |
|
- |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2019-01-18 |
4 |
OE |
$21.25 |
$3,188 |
D/D |
150 |
7,246 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2019-01-10 |
4 |
AS |
$410.00 |
$734,310 |
D/D |
(1,791) |
12,323 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2019-01-10 |
4 |
OE |
$273.67 |
$490,143 |
D/D |
1,791 |
14,114 |
|
- |
|
| Vagelos P Roy |
Chairman of the Board |
• • – |
2019-01-03 |
4 |
GD |
$0.00 |
$0 |
I/I |
569 |
146,844 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2019-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
323 |
323 |
|
- |
|
| Poon Christine A |
Director |
– • – |
2019-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
323 |
1,113 |
|
- |
|
| Bassler Bonnie L |
Director |
– • – |
2019-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
323 |
323 |
|
- |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2019-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
323 |
1,510 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2019-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
323 |
12,323 |
|
- |
|
| Zoghbi Huda Y |
Director |
– • – |
2019-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
323 |
323 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2019-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
323 |
28,823 |
|
- |
|
| Sing George L |
Director |
– • – |
2019-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
323 |
115,095 |
|
- |
|
| Coles N Anthony |
Director |
– • – |
2019-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
323 |
323 |
|
- |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2018-12-20 |
4 |
AS |
$355.14 |
$663,381 |
D/D |
(1,848) |
7,096 |
|
- |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2018-12-20 |
4 |
OE |
$21.25 |
$14,344 |
D/D |
675 |
8,944 |
|
- |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2018-12-19 |
4 |
D |
$364.42 |
$583,801 |
D/D |
(1,602) |
8,269 |
|
- |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2018-12-19 |
4 |
OE |
$52.03 |
$179,504 |
D/D |
3,450 |
9,871 |
|
- |
|
| Yancopoulos George |
President and Chief Scientific |
• • – |
2018-12-13 |
4 |
GA |
$0.00 |
$0 |
I/I |
118,993 |
602,594 |
|
- |
|
| Yancopoulos George |
President and Chief Scientific |
• • – |
2018-12-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
118,993 |
0 |
|
- |
|
| Yancopoulos George |
President and Chief Scientific |
• • – |
2018-12-13 |
4 |
D |
$377.31 |
$47,184,502 |
D/D |
(125,055) |
118,993 |
|
- |
|
2430 Records found
|
|
Page 38 of 98 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
18.30 (1.71%) 
